Difference between revisions of "Entospletinib (GS-9973)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
Line 7: | Line 7: | ||
# Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. [http://www.bloodjournal.org/content/125/15/2336.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25696919 PubMed] | # Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. [http://www.bloodjournal.org/content/125/15/2336.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25696919 PubMed] | ||
− | [[Category: | + | [[Category:Drugs]] |
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] |
Revision as of 22:36, 13 June 2018
Mechanism of action
Spleen tyrosine kinase (SYK) inhibitor
Preliminary data
CLL
- Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. link to original article PubMed